REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
==== Firearms and criminal justice ==== In 1993, Sanders voted against the Brady Bill, which mandated federal background checks when buying guns and imposed a waiting period on firearm purchasers in the United States; the bill passed by a vote of 238–187. He voted against the bill four more times in the 1990s, explaining that his Vermont constituents saw waiting-period mandates as more appropriately a state rather than a federal matter. Sanders did vote for other gun-control measures. For example, in 1994, he voted for the Violent Crime Control and Law Enforcement Act "because it included the Violence Against Women Act and the ban on certain assault weapons." He was nevertheless critical of the other parts of the bill. Although he acknowledged that "clearly, there are some people in our society who are horribly violent, who are deeply sick and sociopathic, and clearly these people must be put behind bars in order to protect society from them", he maintained that governmental policies played a large part in "dooming tens of millions of young people to a future of bitterness, misery, hopelessness, drugs, crime, and violence" and argued that the repressive policies introduced by the bill were not addressing the causes of violence, saying, "we can create meaningful jobs, rebuilding our society, or we can build more jails." Sanders has at times favored stronger law enforcement and sentencing. In 1996, he voted against a bill that would have prohibited police from purchasing tanks and armored carriers.
They demanded that a domestic revolutionary army should be raised and that the price of bread should be fixed at three sous a pound, that nobles holding senior rank in the army should be dismissed, that armouries should be created for arming the sans-culottes, the departments of State purged, suspects arrested, the right to vote provisionally reserved to sans-culottes only, and a fund set apart for the relatives of those defending their country and for the relief of aged and infirm. According to Hampson, the subject is quite extraordinarily complicated and obscure. The next day all Paris was in arms. Hanriot was ordered to march his National Guard, by this time mostly consisting of sans-culottes, from the town hall to the Palais National. On 2 June 1793, a large force of supposedly 80,000 sans-culottes and National Guards led by Hanriot, surrounded the convention with 160–172 guns. On 4 September, the sans-culottes again invaded the convention. They demanded tougher measures against rising prices and the setting up of a system of terror to root out the counter-revolution. The sans-culottes took an especially active interest in the revolutionary army. A "sans-culotte army" (in a sense, Robespierre's brain-child) was formed in Paris.
== Transportation systems == Link (Rochester), an under-construction BRT line in Rochester, Minnesota, US Link (Saskatoon), an under-construction BRT in Canada Link light rail, operated by Sound Transit, in the region of Seattle, Washington, US Terminal Link, Toronto Airport, Canada San Leandro LINKS, a bus service, California, US Link bus services, a service in Auckland, New Zealand
=== Bio-Chemicals business === Biosimilars Monoclonal Antibodies Amino acids, nucleic acids and related compounds, health care products and other active pharmaceutical ingredients Vitamins, minerals, peptides and plant growth regulators
Sources: en.wikipedia.org
=== Tenure === On August 12, 2022, Stansbury voted to pass the Inflation Reduction Act of 2022. According to a FiveThirtyEight analysis, during the 117th Congress, she voted with President Joe Biden's stated position 100% of the time. When President Donald Trump entered the House chamber for the 2025 Joint Session of Congress, Stansbury held a sign that said "this is not normal" to protest the mass firing of federal workers.
Genetic markers are commonly used in Drosophila research, for example within balancer chromosomes or P-element inserts, and most phenotypes are easily identifiable either with the naked eye or under a microscope. In the list of a few common markers below, the allele symbol is followed by the name of the gene affected and a description of its phenotype. (Note: Recessive alleles are in lower case, while dominant alleles are capitalised.)
The foundation of all biomembranes consists of a bilayer structure of phospholipids. The phospholipid molecule is amphipathic; it contains a hydrophilic polar head and a hydrophobic nonpolar tail. The phospholipid heads interact with each other and aqueous media, while the hydrocarbon tails orient themselves in the center, away from water. These latter interactions drive the bilayer structure that acts as a barrier for ions and molecules. There are various types of phospholipids; consequently, their synthesis pathways differ. However, the first step in phospholipid synthesis involves the formation of phosphatidate or diacylglycerol 3-phosphate at the endoplasmic reticulum and outer mitochondrial membrane. The synthesis pathway is found below:
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.